Clinical Trial Update: Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk" [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating teplizumab for prevention of type 1 diabetes in relatives at risk; trial completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Teplizumab (Teplizumab)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes | Phase 2 | Status: COMPLETED | Results posted: 2020-08-05